Article thumbnail

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

By Thomas E Ichim, Boris Minev, Todd Braciak, Brandon Luna, Ron Hunninghake, Nina A Mikirova, James A Jackson, Michael J Gonzalez, Jorge R Miranda-Massari, Doru T Alexandrescu, Constantin A Dasanu, Vladimir Bogin, Janis Ancans, R Brian Stevens, Boris Markosian, James Koropatnick, Chien-Shing Chen and Neil H Riordan


The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2002). [The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer]. Laryngorhinootologie
  2. (2002). A: Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res
  3. (1985). A: Effect of ascorbic acid on human natural killer cells. Immunol Lett
  4. (2003). A: Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study.
  5. (1974). A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact
  6. (2006). AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation.
  7. (2008). Agadjanyan MG, Reznik BN: Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
  8. (2006). Agadjanyan MG: Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
  9. (2008). Agadjanyan MG: DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther
  10. (2007). Agadjanyan MG: Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
  11. (1994). AH: Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med
  12. (2010). Aigner A: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol
  13. Aird WC: The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 14:R182.
  14. (2008). al: Exosomes as a tumor immune escape mechanism: possible therapeutic implications.
  15. Alexander BD: Fungal infections in transplant and oncology patients.
  16. (2007). Alp NJ: Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond)
  17. (2005). Amano K: T cell abnormalities in systemic lupus erythematosus. Autoimmunity
  18. (1992). American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med
  19. as an Anti-cancer Drug.
  20. (2003). Ascorbate enhances iNOS activity by increasing tetrahydrobiopterin in RAW 264.7 cells. Free Radic Biol Med
  21. (2007). Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA
  22. Ascorbate induces autophagy in pancreatic cancer.
  23. (2003). Ascorbic acid blunts oxidant stress due to menadione in endothelial cells. Arch Biochem Biophys
  24. (2000). Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin.
  25. (1946). Ascorbic acid r, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human. Ann Surg
  26. (1989). Bacteremia and fungemia in the immunocompromised patient.
  27. (1999). Bang YJ: Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology
  28. (2006). Biesalski HK: Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care
  29. (1999). BM: The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic Biol Med
  30. (2005). BN: Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice.
  31. (1996). Bodenham A: Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients.
  32. Brandacher G: Neopterin, a prognostic marker in human malignancies.
  33. Bruchelt G: H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin.
  34. (2000). Bucht A: Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol
  35. (2002). BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med
  36. (1996). C: Sustained levels of ascorbic acid are toxic and immunosuppressive for human T cells.
  37. (2009). Calderon PB: In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem
  38. (2009). Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med
  39. Cancer cachexia.
  40. (2009). Cate H: Activated protein C: a promising drug with multiple effects? Mini Rev Med Chem
  41. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione.
  42. (1992). Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol
  43. Cervellin G: Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost 36:36-429.
  44. (2009). Chiplunkar SV: Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients.
  45. (2009). Cho GJ: Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma.
  46. (2008). Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif
  47. CJ: Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function.
  48. (2009). Claxton DF: SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther
  49. (2003). CN: Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-alpha on endothelial cells. Exp Biol Med (Maywood)
  50. (2010). Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med
  51. (1991). Cotran RS: Recruitment of neutrophils in the local endotoxin response: association with de novo endothelial expression of endothelial leukocyte adhesion molecule-1. Lab Invest
  52. (1998). Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with insulindependent diabetes mellitus.
  53. (1996). Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with noninsulin-dependent diabetes mellitus.
  54. (2008). DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
  55. (2009). Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients. Nephrology (Carlton)
  56. (2002). di Montezemolo LC, Di Cataldo A, et al: Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol
  57. (2006). Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions. Zentralbl Gynakol
  58. (2001). Dimmeler S: Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation
  59. (2001). Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost
  60. (2009). DJ: Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg
  61. (2004). Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother
  62. (1985). DR: The determination of dehydroascorbic acid and ascorbic acid in the serum and synovial fluid of patients with rheumatoid arthritis (RA). Free Radic Res Commun
  63. (2004). Duntau AP: Ascorbic acid in blood serum of patients with pulmonary tuberculosis and pneumonia. Int J Tuberc Lung Dis
  64. (2002). DW: Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry
  65. (2002). E: Sepsis: current concepts in intracellular signaling.
  66. (2009). Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer. Anticancer Res
  67. (1995). et al: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res
  68. (2008). et al: Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways. Free Radic Res
  69. et al: Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.
  70. (2009). et al: Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res
  71. (2008). et al: Expansion of T-cell receptor zeta dim effector T cells in acute coronary syndromes. Arterioscler Thromb Vasc Biol
  72. (2007). et al: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell
  73. (2003). et al: Hypovitaminosis C in hospitalized patients.
  74. (2009). et al: Increased oxidative/ nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem
  75. (2006). et al: Induction of antitumor immunity through xenoplacental immunization.
  76. (2009). et al: Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle
  77. (1992). et al: Serum level of interleukin Ichim et al.
  78. et al: The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg 2004, 99:857-863, table of contents.
  79. (2005). et al: Vitamins E and C are safe across a broad range of intakes.
  80. (2008). Fehm T: Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res
  81. (2007). Frydecka I: Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz)
  82. (1979). Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.
  83. (1999). Fuchs D: Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res
  84. (1999). Fukuhara S: Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. Thromb Res
  85. (2003). Functional alterations in CD11b(+)Gr-1 (+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int Immunopharmacol
  86. (2005). Goudevenos JA: Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation.
  87. Greipp PR: Narrative review: the systemic capillary leak syndrome.
  88. (2004). Haase KK: Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res
  89. (2009). Harmatz P: Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med
  90. (1985). Haverkate F: Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood
  91. (2006). Heinecke JW: Vitamin C fails to protect amino acids and lipids from oxidation during acute inflammation. Free Radic Biol Med
  92. (2008). Heitzer T: Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Biol Med
  93. (0112). High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease.
  94. (2011). High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones
  95. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer.
  96. (0044). High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors.
  97. (2009). High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost
  98. (2004). Huhle G: Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine
  99. (2007). Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med
  100. (2007). Ichim TE: Therapeutic use of Aldara in chronic myeloid leukemia.
  101. (1997). Influence of ascorbic acid on the response to mitogens and interleukin production of porcine lymphocytes.
  102. (2001). Innate immunity and inflammation: a transcriptional paradigm. Immunol Res
  103. Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer.
  104. (2006). Intravenously administered vitamin C as cancer therapy: three cases. CMAJ
  105. (2009). Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis
  106. Iso H: Serum vitamin C concentration and hs-CRP level in middle-aged Japanese men and women.
  107. (1995). JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses
  108. (2006). JB: CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress.
  109. (2002). JL: Activated protein C for severe sepsis.
  110. (2006). JW: Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets
  111. (2002). JX: Ascorbate inhibits iNOS expression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett
  112. (2005). JX: Delayed ascorbate bolus protects against maldistribution of microvascular blood flow in septic rat skeletal muscle. Crit Care Med
  113. (2008). JX: Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. Crit Care Med
  114. (2001). Kanetake H: Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology
  115. (2003). Katusic ZS: Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res
  116. (2003). Kinasewitz GT: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost
  117. (1999). Kooner JS: Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation
  118. (2009). L: Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer.
  119. L: The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer.
  120. (2000). LA: Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase.
  121. Laggner H: Vitamin C inhibits NO-induced stabilization of HIF-1alpha in HUVECs. Free Radic Res
  122. (2008). Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol
  123. (2008). Lampugnani MG: The role of adherens junctions and VE-cadherin in the control of vascular permeability.
  124. (2006). Laurindo FR: Redox mechanisms of vascular cell dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets
  125. (1996). LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.
  126. (2004). LO: Antioxidant intervention blunts renal injury in experimental renovascular disease.
  127. (2009). Lopez-Soriano FJ: The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care
  128. (1985). Loskutoff DJ: Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA
  129. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer.
  130. (2002). Maier RV: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg
  131. (1952). Markardt B: Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer
  132. (1995). Mayumi T: Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer.
  133. McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.
  134. (2009). Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors
  135. (2009). Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
  136. (2004). Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem
  137. (2009). MK: Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev
  138. (2007). MM: Downregulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. Anal Quant Cytol Histol
  139. (1985). MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.
  140. (2003). Modulation of TNF-alpha-induced ICAM-1 expression, NO and H2O2 production by alginate, allicin and ascorbic acid in human endothelial cells. Arch Pharm Res
  141. (1996). Munzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation
  142. (2003). Neutropenia and the development of the systemic inflammatory response syndrome. Intensive Care Med
  143. (1984). Neutrophils kill pulmonary endothelial cells by a hydrogenperoxide-dependent pathway. An in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis
  144. (2008). NH: Anti-angiogenic effect of high doses of ascorbic acid.
  145. NH: Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo.
  146. (2008). NH: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate.
  147. (1998). Nitric oxide in sepsis and endotoxaemia.
  148. (2003). Novel function of ascorbic acid as an angiostatic factor. Angiogenesis
  149. (1996). Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/ action through beta2 integrin in vivo.
  150. (1996). NR: Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med
  151. (1997). O’Neill LA: Vitamin C inhibits NF kappa B activation in endothelial cells. Biochem Soc Trans
  152. (2001). OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of tcell function in advanced cancer patients. Cancer Res
  153. (2006). Oleinik EK: A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures.
  154. (2003). Opal SM: The Toll-like receptors and their role in septic shock. Expert Opin Ther Targets
  155. (1965). Oxidation of L-ascorbic acid by cells of carcinoma of the human cervix. Nature
  156. (2006). PA: C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov
  157. (2003). Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium.
  158. (1976). Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA
  159. (2008). Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA
  160. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormonerefractory prostate cancer.
  161. (2009). Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist
  162. (1996). PM: Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med
  163. (2007). Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus.
  164. (2004). Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr Vasc Pharmacol
  165. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer.
  166. (1982). Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate.
  167. (2007). PS: Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther
  168. Qu ZC: Ascorbic acid prevents increased endothelial permeability caused by oxidized low density lipoprotein. Free Radic Res 44:44-1359.
  169. (2009). Radi R: Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol
  170. (2000). Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg
  171. (2008). Rochette L: Plasma antioxidant status in septic critically ill patients: a decrease over time. Fundam Clin Pharmacol
  172. (1991). Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res
  173. (2006). RS: Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies.
  174. (2002). S: Chemical stabilization of tetrahydrobiopterin by L-ascorbic acid: contribution to placental endothelial nitric oxide synthase activity. Mol Hum Reprod
  175. (2009). S: Errors in the approval process and postmarketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis
  176. (2009). S: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis.
  177. S: High dose of ascorbic acid induces cell death in mesothelioma cells.
  178. (2006). S: TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NFkappaB- and p38 MAPK-dependent. J Thromb Haemost
  179. (2000). SA: Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat
  180. (2002). SA: Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med
  181. (2009). Sandrock CE: Bench-to-bedside review: the role of nitric oxide in sepsis. Expert Rev Respir Med
  182. (2003). Sauberlich HE: Ascorbic acid dynamics in the seriously ill and injured.
  183. (1997). Scheper RJ: T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut
  184. (1982). Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyterelated host resistance.
  185. (1998). Scurvy in patients with cancer. BMJ
  186. (2004). Seals DR: Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing.
  187. (2008). Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost
  188. (2002). Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant
  189. (2005). Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
  190. (2005). Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer
  191. (2009). SF: A pivotal role of endothelial-specific NFkappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction.
  192. (2001). SF: Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009, 114:2521-2529. Ichim et al.
  193. SF: Selective blockade of endothelial NFkappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice.
  194. (2007). Song KJ: Changes of terminal cancer patients’ healthrelated quality of life after high dose vitamin C administration.
  195. (2001). Spek CA, Reitsma PH: Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med
  196. (2009). Sun CF: C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J
  197. (2008). survival and the acute phase response. Curr Opin Support Palliat Care
  198. Systemic Inflammatory Response Syndrome (SIRS) Prognosis.
  199. (2004). T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med
  200. (2009). TCR zeta chain expression in T cells from patients with CML. Hematology
  201. (2006). TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs.
  202. (2004). TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol
  203. The coagulant response in sepsis and inflammation.
  204. (1989). The endothelium-derived relaxing factor.
  205. The multiple actions of NO.
  206. (2004). The role of monocytes/ macrophages in TCR-zeta chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents
  207. (2005). The role of nitric oxide in cardiovascular diseases. Mol Aspects Med
  208. (2011). Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost
  209. (1995). Tissue factor expression in endothelial cells in health and disease. Blood Coagul Fibrinolysis
  210. (1998). TL: Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res
  211. (2010). TM: C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol
  212. (1973). Townsley BH: The effect of L-ascorbate on catecholamine biosynthesis.
  213. (2003). Tracey KJ: HMGB1 in sepsis.
  214. (2005). Trentz O: Pathophysiology of polytrauma. Injury
  215. (0105). Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective.
  216. (1967). Tsai SF: Investigation of ascorbic acid levels in blood of cancer patients compared to normal subjects. Mo Med
  217. (2002). Tsokos GC: Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes. Cell Immunol
  218. (2004). Tsokos GC: TCR zeta-chain abnormalities in human systemic lupus erythematosus. Methods Mol Med
  219. (2000). Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood
  220. (2003). Tyml K: Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in skeletal muscle of septic mice.
  221. (2004). Tyml K: Ascorbate protects against impaired arteriolar constriction in sepsis by inhibiting inducible nitric oxide synthase expression. Free Radic Biol Med
  222. (1999). U: L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells.
  223. (2003). van Oers NS: T-cell receptor signal transmission: who gives an ITAM? Trends Immunol
  224. (1997). Verweij CL: Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis.
  225. (1996). Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of
  226. (2007). Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis
  227. (2005). Vitamin C deficiency in cancer patients. Palliat Med
  228. (1997). Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation
  229. (2007). Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother
  230. (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med
  231. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5:e11414.
  232. (2003). Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension
  233. (1998). WE: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry
  234. Wiersinga WJ: The systemic pro-inflammatory response in sepsis.
  235. (2009). WX: Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res
  236. (2009). Y: Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas
  237. (2003). Zheng SB: Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms.
  238. (2003). Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med